Gothenburg, February 18, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today announces that updated clinical data from the ongoing Phase I/IIa CARMA study with its lead CAR T-cell therapy candidate ELC-301 will be presented on March 6, 2026 at the 10th Zurich Immuno-Oncology Conference 2026 in Zürich, Switzerland.
The update will be presented by the Company’s Chief Scientific Officer, Professor Magnus Essand, during an invited scientific presentation at the 10th Zurich Immuno-Oncology Conference 2026 in Zürich, Switzerland. The conference, held at Universitätsspital Zürich, brings together leading researchers and clinicians to discuss innovations in immuno-oncology.
The presentation will include new data from two patients enrolled in cohort 3 (the highest dose level to date) of the CARMA study, as well as longer-term follow-up data from patients treated in the previous two cohorts (dose levels 1 and 2).
The CARMA study is evaluating the safety and preliminary efficacy of ELC-301, an autologous CD20-directed CAR T-cell therapy armed with the company’s iTANK-technology, in patients with relapsed or refractory B-cell lymphoma.
Previous updates from the first two cohorts (presented e.g. at the Karolinska ATMP Center inauguration in August 2025) showed promising signals, including complete metabolic responses in four of six treated patients, a favorable safety profile, and no dose-limiting toxicities observed to date.
“We are pleased to share the next data update from the CARMA study in this prestigious scientific forum,” said Professor Magnus Essand, Chief Scientific Officer of Elicera Therapeutics. “The presentation will highlight our efforts to optimize CAR T-cell performance through the iTANK platform, aiming for enhanced anti-tumor activity while minimizing toxicity – key challenges in solid and hematological malignancies.”
The company expects to issue a separate press release with key highlights from the presentation in connection with the event on March 6, 2026.
For more information: https://www.usz.ch/en/event/10th-zurich-immuno-oncology-conference-2026/
For further information, please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
Certified Advisor
DNB Carnegie Investment Bank AB (publ)
About the CARMA Study
CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapy ELC-301 in the treatment of patients with B-cell lymphoma. The study is divided into a dose-escalation phase (phase I) and a dose-expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. Phase I is planned to include three cohorts (dosing groups), with three patients in the first and second cohorts, and six patients in the third dcohort, who are expected to receive the maximum tolerated dose. The CARMA study is being conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge.
About ELC-301
ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company’s iTANK platform to activate a broader and more comprehensive parallel immune response against cancer. CAR T-cells are a form of cell therapy created by genetically modifying a patient’s T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen—a molecule visible on the surface of cancer cells—and enables the T-cells to locate, bind to, and destroy the cancer cells.
About the iTANK platform
The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company’s own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled “CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK platform is available here: https://www.elicera.com/technology
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.